Dr. Katharine J. Bar, MD

Dr. Bar practices at Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr) in Philadelphia, Pennsylvania.

Dr. Bar's NPI, 1942337670, was assigned on February 28, 2007. Dr. Bar graduated from University of Iowa, RJ & L Carver College of Medicine in 2002. Dr. Bar holds Pennsylvania license MD443933.

Dr. Bar's primary practice is Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr), at 3400 Spruce Street, White Bldg 1st Flr, Philadelphia, PA 19104.

Dr. Bar's primary practice is Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr) in Philadelphia, Pennsylvania. Dr. Bar is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health. Dr. Bar's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bar practices, 2 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Bar's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dmand AI has Dr. Bar's licenses on file in 2 states: Pennsylvania and Alabama.

CMS data shows 17 Medicare services from Dr. Bar across 1 procedure code in 2024, all of them office visits, for 37 Medicare patients. Medicare paid $1,022 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 37 Medicare patients who saw Dr. Bar in 2024. The largest group is 65 to 74, with 16 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 41% are also on Medicaid. Their average risk score is 3.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bar's median patient age at 59, with 48% women.

In 2024, Dr. Bar wrote 587 Medicare Part D claims for 33 patients. 60% of them were for generic drugs. CMS names the drug for 477 of them, across 23 drugs with 11 or more claims each, at $844,598 in total drug cost. In 2023, CMS named 621 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Bar for performance year 2024, reported as part of a group. Dr. Bar accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Bar to 1 clinical trial. Open Payments lists research payments to Dr. Bar that name 1 trial.

CMS Open Payments shows 26 general payments to Dr. Bar from 4 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 94% of the total. Merck Sharp & Dohme Corporation paid the most, $11,600. It also lists 14 research payments totaling $6,892 from 2021 to 2024, naming 1 clinical trial.

Dr. Bar graduated from University of Iowa, RJ & L Carver College of Medicine in 2002.